Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Lu AF88434 in Healthy Young Men
NCT04082325Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lu AF88434 in schizophrenia (4 arms), sponsored by Lundbeck. Primary endpoints: Number of participants with treatment-emergent adverse events, Maximum observed plasma concentration (Cmax) of Lu AF88434 and 3 more. Started Jul 2019; status: completed.
02
Drugs
Lu AF88434
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04082325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082325.